// App-Quantinova.ai

e11535 : AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis.

Researchers

Presenter

  • Javier Salvador

Principal Investigators

  • Eva M. Ciruelos

  • Manuel Codes

  • Juan L. Bayo

  • Isabel Blancas

  • Encarnacion Gonzalez

  • Diego Perez

  • Jose Ramon Mel

  • Luis Manso

  • Ana Jaen

  • Miquel Gil

  • Antonio Galan

  • Adolfo Murias

  • Carlos Jara-Sanchez

  • Juan De la Haba- Rodriguez

  • Jose Manuel Baena

  • Maria Jose Villanueva Silva

Medical Centers

  • Hospital Universitavio Insular De Gran Canaria, Las Palmas, Spain

  • Fundacion Hospital Alcorcon, Madrid, Spain

  • Hospital Costa del Sol, Malaga, Spain

  • Instituto Catalan de Oncologia, Bellvitge, Spain

  • Complejo Hospitalario Xeral Cies, Vigo, Spain

  • Hospital Ciudad de Jaen, Jaen, Spain

  • Hospital Clinico San Cecilio, Granada, Spain

  • Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Pharmacy, Hospital Juan Ramon Jimenez, Huelva, Spain

  • Pharmacy, Hospital Virgen Macarena, Sevilla, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Bevacizumab

  • Gemcitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved